Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and JIUN-KAE JACK LEE.
ADEL K EL-NAGGAR
Connection Strength
1.030
JIUN-KAE JACK LEE
  1. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene. 2002 Nov 21; 21(53):8206-19.
    View in: PubMed
    Score: 0.217
  2. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett. 2006 Jul 28; 239(1):136-43.
    View in: PubMed
    Score: 0.066
  3. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004 Aug; 6(3):180-90.
    View in: PubMed
    Score: 0.061
  4. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May; 6(5):1702-10.
    View in: PubMed
    Score: 0.046
  5. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol. 1997 Dec; 151(6):1767-74.
    View in: PubMed
    Score: 0.038
  6. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6582-92.
    View in: PubMed
    Score: 0.031
  7. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73.
    View in: PubMed
    Score: 0.024
  8. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila). 2011 Feb; 4(2):218-29.
    View in: PubMed
    Score: 0.024
  9. Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. J Biomed Opt. 2010 Nov-Dec; 15(6):066017.
    View in: PubMed
    Score: 0.024
  10. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010 Jul; 3(7):800-9.
    View in: PubMed
    Score: 0.023
  11. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.
    View in: PubMed
    Score: 0.023
  12. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.022
  13. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
    View in: PubMed
    Score: 0.022
  14. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 01; 15(19):6284-91.
    View in: PubMed
    Score: 0.022
  15. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila). 2009 May; 2(5):423-31.
    View in: PubMed
    Score: 0.021
  16. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer. 2009 Apr 15; 115(8):1669-79.
    View in: PubMed
    Score: 0.021
  17. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
    View in: PubMed
    Score: 0.021
  18. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
    View in: PubMed
    Score: 0.021
  19. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101.
    View in: PubMed
    Score: 0.020
  20. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008 Jan 20; 26(3):354-60.
    View in: PubMed
    Score: 0.019
  21. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res. 2007 Nov 01; 13(21):6532-9.
    View in: PubMed
    Score: 0.019
  22. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007 Jun 01; 25(16):2164-70.
    View in: PubMed
    Score: 0.019
  23. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006 Aug 01; 107(3):563-9.
    View in: PubMed
    Score: 0.018
  24. Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006 May 15; 12(10):3109-14.
    View in: PubMed
    Score: 0.017
  25. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
    View in: PubMed
    Score: 0.017
  26. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. Laryngoscope. 2005 Sep; 115(9):1561-7.
    View in: PubMed
    Score: 0.016
  27. Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer. 2005 Mar 01; 103(5):952-9.
    View in: PubMed
    Score: 0.016
  28. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65.
    View in: PubMed
    Score: 0.016
  29. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res. 2004 Aug 15; 10(16):5554-7.
    View in: PubMed
    Score: 0.015
  30. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004 Apr 01; 350(14):1405-13.
    View in: PubMed
    Score: 0.015
  31. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003 Feb 05; 95(3):198-205.
    View in: PubMed
    Score: 0.014
  32. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.014
  33. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol Biomarkers Prev. 2002 Dec; 11(12):1605-10.
    View in: PubMed
    Score: 0.014
  34. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res. 2000 Jul; 6(7):2821-8.
    View in: PubMed
    Score: 0.012
  35. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther. 2000 Apr; 7(4):530-6.
    View in: PubMed
    Score: 0.011
  36. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst. 2000 Jan 05; 92(1):69-73.
    View in: PubMed
    Score: 0.011
  37. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
    View in: PubMed
    Score: 0.011
  38. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.